These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37762951)

  • 1. Portrait of Dysferlinopathy: Diagnosis and Development of Therapy.
    Bouchard C; Tremblay JP
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy.
    Lee JJA; Maruyama R; Duddy W; Sakurai H; Yokota T
    Mol Ther Nucleic Acids; 2018 Dec; 13():596-604. PubMed ID: 30439648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysferlin and animal models for dysferlinopathy.
    Kobayashi K; Izawa T; Kuwamura M; Yamate J
    J Toxicol Pathol; 2012 Jun; 25(2):135-47. PubMed ID: 22907980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limb-Girdle Muscular Dystrophy 2B and Miyoshi Presentations of Dysferlinopathy.
    Patel NJ; Van Dyke KW; Espinoza LR
    Am J Med Sci; 2017 May; 353(5):484-491. PubMed ID: 28502335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous characteristics of Korean patients with dysferlinopathy.
    Park HJ; Hong JM; Suh GI; Shin HY; Kim SM; Sunwoo IN; Suh BC; Choi YC
    J Korean Med Sci; 2012 Apr; 27(4):423-9. PubMed ID: 22468107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities.
    Poudel BH; Fletcher S; Wilton SD; Aung-Htut M
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysferlinopathy misdiagnosed with juvenile polymyositis in the pre-symptomatic stage of hyperCKemia: a case report and literature review.
    Contreras-Cubas C; Barajas-Olmos F; Frayre-Martínez MI; Siordia-Reyes G; Guízar-Sánchez CC; García-Ortiz H; Orozco L; Baca V
    BMC Med Genomics; 2022 Jun; 15(1):139. PubMed ID: 35725460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dysferlin expression in limb-girdle muscular dystrophy and Miyoshi myopathy: analysis of 45 cases].
    Ren SC; Yan CZ; Li MX; Liu SP; Wu JL; Zhao YY; Li W; Li DN
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1486-90. PubMed ID: 17785089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morpholino-Mediated Exons 28-29 Skipping of Dysferlin and Characterization of Multiexon-skipped Dysferlin using RT-PCR, Immunoblotting, and Membrane Wounding Assay.
    Anwar S; Yokota T
    Methods Mol Biol; 2023; 2587():183-196. PubMed ID: 36401031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysferlin at transverse tubules regulates Ca(2+) homeostasis in skeletal muscle.
    Kerr JP; Ward CW; Bloch RJ
    Front Physiol; 2014; 5():89. PubMed ID: 24639655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy.
    Yin X; Wang Q; Chen T; Niu J; Ban R; Liu J; Mao Y; Pu C
    Int J Clin Exp Pathol; 2015; 8(3):3069-75. PubMed ID: 26045819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exon Skipping in a Dysf-Missense Mutant Mouse Model.
    Malcher J; Heidt L; Goyenvalle A; Escobar H; Marg A; Beley C; Benchaouir R; Bader M; Spuler S; García L; Schöwel V
    Mol Ther Nucleic Acids; 2018 Dec; 13():198-207. PubMed ID: 30292141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid screening for Japanese dysferlinopathy by fluorescent primer extension.
    Hayashi S; Ohsawa Y; Takahashi T; Suzuki N; Okada T; Rikimaru M; Murakami T; Aoki M; Sunada Y
    Intern Med; 2010; 49(24):2693-6. PubMed ID: 21173544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miyoshi Muscular Dystrophy Type 1 with Mutated
    Park J; Moon YJ; Kim DS
    Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile.
    Belhassen I; Laroussi S; Sakka S; Rekik S; Lahkim L; Dammak M; Authier FJ; Mhiri C
    Neuromuscul Disord; 2023 Oct; 33(10):718-727. PubMed ID: 37716854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compound heterozygous DYSF variants causing limb-girdle muscular dystrophy type 2B in a Chinese family.
    Li L; Jing Z; Cheng L; Liu W; Wang H; Xu Y; Zheng X; Yu X; Liu S
    J Gene Med; 2020 Nov; 22(11):e3272. PubMed ID: 32889728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DYSF mutation analysis in a group of Chinese patients with dysferlinopathy.
    Zhao Z; Hu J; Sakiyama Y; Okamoto Y; Higuchi I; Li N; Shen H; Takashima H
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1234-7. PubMed ID: 23254335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism.
    Cenacchi G; Fanin M; De Giorgi LB; Angelini C
    J Clin Pathol; 2005 Feb; 58(2):190-5. PubMed ID: 15677541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of Targeted RNA-Seq for the Resolution of Variant Pathogenicity and Enhancement of Diagnostic Yield in Dysferlinopathy.
    Rufibach L; Berger K; Chakravorty S; Emmons S; Long L; Gibson G; Hegde M
    J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983702
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.